NANOBIOTIX (NANO)

NANOBIOTIX
Sell: €2.90|Buy: €2.99|Change: 0.12 (4.20%)

Company profile

Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.

Address





Sector 

Healthcare


Previous key dates

NameKey Date
Nanobiotix SA Annual General Meeting for 20252025-05-28T14:00:00
Nanobiotix SA First Quarter Earnings Conference Call for 20252025-05-22T08:00:00
Nanobiotix SA First Quarter Earnings Results for 20252025-05-22T00:00:00
Full Results Phase 1 Pancreas (ESTRO 2025)2025-05-05T08:00:00
Nanobiotix SA Fourth Quarter Earnings Conference Call for 20242025-04-03T08:00:00
Nanobiotix SA Fourth Quarter Earnings Results for 20242025-04-02T00:00:00
Nanobiotix SA Annual Report for 20242025-04-02T00:00:00
Nanobiotix Update Call2025-03-18T08:30:00
Leerink Global Healthcare Conference2025-03-12T22:40:00
Guggenheim SMID Cap Biotech Conference2025-02-06T13:00:00
Accelerating the Future of Nanotherapeutics2024-12-19T15:00:00
Jefferies London Healthcare Conference2024-11-20T08:00:00
Stifel Healthcare Conference2024-11-18T16:45:00
Nanobiotix SA Third Quarter Earnings Results for 20242024-11-12T00:00:00
Nanobiotix SA Third Quarter Earnings Conference Call for 20242024-11-12T00:00:00
Guggenheim's Inaugural Healthcare Innovation Conference2024-11-11T16:00:00
Nanobiotix SA Second Quarter Earnings Result for 20242024-09-18T00:00:00
Nanobiotix SA Second Quarter Earnings Conference Call for 20242024-09-18T00:00:00
H.C. Wainwright 26th Annual Global Investment conference2024-09-11T09:30:00
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference2024-06-05T17:00:00
Nanobiotix Investor Call2024-06-02T12:00:00
Nanobiotix SA Annual General Meeting for 20242024-05-28T14:00:00
Nanobiotix SA First Quarter Earnings Conference Call for 20242024-05-22T08:00:00
Nanobiotix SA First Quarter Earnings Result for 20242024-05-22T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.